3 Stocks I Saw on T...
Health Care: Drugs
Cubist Pharmaceuticals Inc. (CBST: NASDAQ)
$39.93 0.26 | 0.66%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 72.10 | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | 77.90 | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | 6.30 | 18.60 | 12.50 |
| Beta | 0.57 | 0.62 | 0.98 |
| Price to Sales (TTM) | 3.13 | 4.29 | 1.42 |
| Price to Book (MRQ) | 2.94 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 4.46 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | 28.50 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -24.10 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 30.20 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 18.50 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 26.79 | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | 45.20 | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | 45.20 | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | 13.96 | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 84.47 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.40 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 5.90 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.54 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.54 | 0.37 | 0.96 |
| Interest Coverage (TTM) | 4.70 | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 81.90 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 82.60 | 75.30 | 47.70 |
| EBITD Margin (TTM) | 25.20 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | 14.45 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 14.80 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 17.70 | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.05 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 15.90 | 8.60 | 7.00 |
| Return on Assets (TTM) | 2.30 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | 7.70 | 4.60 | 2.50 |
| Return on Investment (TTM) | 3.30 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | 10.30 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 1,200,498.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | 64,622.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 10.60 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 4.90 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 0.50 | 0.60 | 0.40 |
Portfolios with CBST
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 6
- ContributorStocks At New 52-Week Highs...
- ContributorTop-Rated Biotechnology Stocks
- ContributorEarnings Short Squeeze Play...
- ContributorStocks At New 52-Week Highs...
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- ProJoel Greenblatt - Gotham Ca...
- ContributorEarnings Short Squeeze Play...
Latest CBST Headlines from TheStreet
- Upgrades Roundup: TXT, CBST, BK, MCP, AVP, LFL, SHO, BPI 04.23.12 | 06:04 am
- Cubist Pharmaceuticals Inc. Stock Upgraded (CBST) 04.20.12 | 05:04 am
- 5 Stocks Poised to Pop on Earnings 04.18.12 | 07:04 am
- Cubist Stock Hits New 52-Week High (CBST) 03.26.12 | 11:03 am
- Cubist Stock Hits New 52-Week High (CBST) 03.09.12 | 10:03 am
- Cubist Reaches New 52-Week High (CBST) 02.22.12 | 03:02 pm
- Cubist Stock Hits New 52-Week High (CBST) 02.03.12 | 10:02 am
- TheStreet Ratings Top 10 Rating Changes 01.23.12 | 12:01 pm
- Cubist Pharmaceuticals Inc. Stock Downgraded (CBST) 01.23.12 | 05:01 am
- 5 Stocks Set to Soar on Bullish Earnings 01.18.12 | 03:01 pm
Press Releases for CBST
- Cubist Pharmaceuticals Marks 20th Anniversary By Making Its Largest-Ever Commitment To STEM Programs - Business Wire 05.16.12 | 09:05 am
- Cubist Pharmaceuticals To Present At May Investor Conference - Business Wire 05.07.12 | 10:05 am
- Cubist Announces Positive Results From ENTEREG® Phase 4 Study In Patients Undergoing Radical Cystectomy - Business Wire 04.17.12 | 05:04 pm
- Cubist Pharmaceuticals To Announce Q112 Financial Results On Wednesday, April 18th, 2012 - Business Wire 04.02.12 | 10:04 am
- Senator Scott Brown And Cubist Pharmaceutical President And CEO Michael Bonney (right) And Steven Gilman, Executive Vice President, Research & Development And Chief Scientific Officer. - Business Wire 03.16.12 | 12:03 pm
- Cubist Pharmaceuticals Appoints Jane Henney To Board Of Directors - Business Wire 03.09.12 | 08:03 am
- Cubist Pharmaceuticals To Present At February/March Investor Conferences - Business Wire 02.20.12 | 11:02 am
- Cubist Pharmaceuticals Appoints Alison Lawton To Board Of Directors - Business Wire 02.16.12 | 08:02 am
- Cubist Receives CUBICIN Paragraph IV Notice Letter - Business Wire 02.09.12 | 07:02 am
- Cubist Pharmaceuticals Reports 2011 Fourth Quarter And Full Year Financial Results - Business Wire 01.19.12 | 04:01 pm
Partner Headlines for CBST
- After Hours Most Active for Jun 1, 2012 : BAC, QQQ, MSFT, JPM, KITD, SWK, WFC, WMB, MET, STX, CBST, INTC - NASDAQ 06.01.12 | 08:06 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medical Stocks Forming Bases Amid Market Sell-Off - Investor's Business Daily 05.18.12 | 06:05 pm
- Big Pharma Abandons Antibiotics: An Opening For Small Biotech - Seeking Alpha 05.13.12 | 09:05 am
- 2 Low-Growth Pharma Behemoths: Merck, J&J - Seeking Alpha 05.01.12 | 09:05 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Alnylam Delivers In-Line Numbers - Analyst Blog - Zacks 02.13.12 | 10:02 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- Cubist's Preliminary Sales Impress - Analyst Blog - Zacks 01.11.12 | 10:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
